# US 2005/0038019 A1 · Hydroxy substituted amides for the treatment of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0038019 A1
- Document ID: US20050038019A1
- Status: Published application
- Kind: A1
- Application number: 10/494,184
- Filed: 2002-10-29
- Published: 2005-02-17
- Earliest claimed: 2001-10-29
- Inventors: James Beck
- Web page: https://patentgrep.com/patent/US20050038019A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/195: having an amino group
- A61K 31/38: having sulfur as a ring hetero atom
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/426: 1,3-Thiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/537: spiro-condensed or forming part of bridged ring systems
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is a method of treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of known compounds of Formula (I), wherein, A, R, J, and n are as defined herein.

## Claims

### Claim 1

A method of treating or preventing Alzheimer's disease in a subject in need of such treatment comprising administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein
A is
1) aryl unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl; or
2) a 5- to 10-membered mono or bicyclic heterocycle in which one or both heterocyclic rings contain an atom selected from N, O, or S, which heterocycle is unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl;
n is an integer from 1-6;
R is
1) aryl, unsubstituted or substituted with C1-4 lower alkyl, C1-4 lower alkoxy, or halo, or
2) C3-7 cycloalkyl;
R1 is C1-4 lower alkyl, C3-7cycloalkyl or H; and
J is:

### Claim 2 (depends on 1)

A method of treating Alzheimer's disease in a subject in need of such treatment comprising administering to the subject a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A method of treating Alzheimer's disease by modulating the activity of beta amyloid converting enzyme, comprising administering to a subject in need of such treatment a compound disclosed in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising the administration of a P-gp inhibitor, or a pharmaceutically acceptable salt thereof.

### Claim 5

A method of treating a subject who has, or in preventing a subject from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating subjects with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, frontotemporal dementias with parkinsonism (FTDP), dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which includes administration of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein
A is
1) aryl unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl; or
2) a 5- to 10-membered mono or bicyclic heterocycle in which one or both heterocyclic rings contain an atom selected from N, O, or S, which heterocycle is unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl;
n is an integer from 1-6;
R is
1) aryl, unsubstituted or substituted with C1-4 lower alkyl, C1-4 lower alkoxy, or halo, or
2) C3-7 cycloalkyl;
R1 is C1-4 lower alkyl, C3-7cycloalkyl or H; and
J is:

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound is
wherein X is COOR1; CONHR1; SO2NHR1, or SO2R1;
R1 is C1-4 lower alkyl, C3-7cycloalkyl or H;
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound is
and X is CONHR1 or SO2NHR1,
R1 is C1-4 lower alkyl, C3-7cycloalkyl or H;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 11

(cancelled)

### Claim 12

A method of treating or preventing Alzheimer's disease in a subject in need of such treatment comprising administering a therapeutically effective amount of a composition comprising one or more pharmaceutically acceptable carriers and a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
wherein
A is
1) aryl unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl; or
2) a 5- to 10-membered mono or bicyclic heterocycle in which one or both heterocyclic rings contain an atom selected from N, O, or S, which heterocycle is unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl;
n is an integer from 1-6;
R is
1) aryl, unsubstituted or substituted with C1-4 lower alkyl, C1-4 lower alkoxy, or halo, or
2) C3-7 cycloalkyl;
R1 is C1-4 lower alkyl, C3-7cycloalkyl or H; and
J is:

### Claim 13

(cancelled)

### Claim 14

A method for inhibiting beta-secretase activity, comprising contacting an effective amount for inhibition of a compound of formula (I):
wherein
A is
1) aryl unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl; or
2) a 5- to 10-membered mono or bicyclic heterocycle in which one or both heterocyclic rings contain an atom selected from N, O, or S, which heterocycle is unsubstituted or substituted with one or more of
a) C1-4 lower alkyl;
b) hydroxy;
c) halo;
d) C1-4 lower or branched alkoxy;
e) C1-4 lower branched thioalkyl;
f) COOR1;
g) CONHR1;
h) SO2NHR1;
i) SO2R1; or
j) C1-4 lower hydroxyalkyl;
n is an integer from 1-6;
R is
1) aryl, unsubstituted or substituted with C1-4 lower alkyl, C1-4 lower alkoxy, or halo, or
2) C3-7 cycloalkyl;
R1 is C1-4 lower alkyl, C3-7cycloalkyl or H; and
J is:

### Claim at position 15

15-24. (cancelled)

### Claim 25 (depends on 1)

A method of treatment according to claim 1, further comprising administration of one or more therapeutic agents selected from the group consisting of an antioxidant, an anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetyl cholinesterase inhibitor, a statin, P-gp inhibitors, an A beta peptide, and an anti-A beta peptide.

### Claim 26

(cancelled)

### Claim 27 (depends on 1)

A method according to claim 1 wherein the compound is selected from the group consisting of:
2-((2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl)-N-butylbenzamide;
(2R,4S)-2-benzyl-5-{2-[(butylamino)sulfonyl]phenyl}-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
2-((2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl)-N-butyl-5,6,7,8-tetrahydronaphthalene-1-carboxamide;
(2R,4S)-5-[2-(aminosulfonyl)phenyl]-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
2-((2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl)-5,6,7,8-tetrahydronaphthalene-1-carboxamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(5-methylthien-2-yl)pentanamide;
(2R,4S)-5-(1-benzothien-2-yl)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
(2R,4S)-2-benzyl-5-(1,1-dioxido-1-benzothien-2-yl)-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-[1-(methoxymethyl)-1H-indol-2-yl]pentanamide;
(2R,4S)-2-benzyl-5-(1,1′-biphenyl-2-yl)-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
(2R,4S)-2-benzyl-5-[2-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-4-methylphenyl]-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-[2-(hydroxymethyl)phenyl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(2-methoxyphenyl)pentanamide;
2-((2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl)-N-(tert-butyl)-5-methylbenzamide;
(2R,4S)-2-benzyl-5-(2-ethoxyphenyl)-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
2-((2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl)benzyl butylcarbamate;
(2R,4S)-2-benzyl-5-(2,5-dimethoxyphenyl)-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(2-hydroxyphenyl)pentanamide;
(2R,4S)-2-benzyl-5-(2,4-dimethoxyphenyl)-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
(2R,4S)-2-benzyl-5-(3,5-dibromo-2-hydroxyphenyl)-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-5-(2-isobutoxyphenyl)pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-[2-(methylthio)phenyl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-phenylpentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-[2-(methylsulfonyl)phenyl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-[2-(methoxymethoxy)phenyl]pentanamide;
(2R,4S)-2-benzyl-4-hydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(2-methoxy-4-phenoxyphenyl)pentanamide;
or a pharmaceutically acceptable salt or mixture thereof.
